- Home
- ABVX
ABVX
Abivax SA American
as 11-15-2024 4:00pm EST
Stocks
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.
| Founded: | 2013 | Country: | France |
| Employees: | N/A | City: | N/A |
| Market Cap: | 722.3M | IPO Year: | N/A |
| Target Price: | $36.50 | AVG Volume (30 days): | 82.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.75 - $17.02 | Next Earning Date: | 09-09-2024 |
| Revenue: | $9,676,417 | Revenue Growth: | 100.87% |
| Revenue Growth (this year): | 31.67% | Revenue Growth (next year): | 1189.66% |
Latest Abivax SA American News
ABVX Breaking Stock News: Dive into ABVX Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Abivax presents third quarter 2024 key financial information
GlobeNewswire
3 days ago
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax
GlobeNewswire
a month ago
Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation
GlobeNewswire
a month ago
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease
GlobeNewswire
a month ago
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance
GlobeNewswire
2 months ago
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
GlobeNewswire
2 months ago
Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model
GlobeNewswire
2 months ago
Abivax presents first-half 2024 financial results
Compare ABVX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ABVX Abivax SA American - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.